Clinical Trials
12 trialsNCT04250545 2026-05-26
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02142803 2026-04-29
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02159989 2025-10-20
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT03154294 2024-07-26
Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors
Avera McKennan Hospital & University Health Center
Phase 1 Completed
NCT03370302 2023-02-08
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies
Calithera Biosciences, Inc
Phase 1 Terminated
NCT02197572 2023-01-23
Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors
Calithera Biosciences, Inc
Phase 1 Completed
NCT02719691 2022-07-25
Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer
University of Colorado, Denver
Phase 1 Completed
NCT01058707 2020-04-01
Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies
Takeda
Phase 1 Completed
NCT02412722 2020-02-28
A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies
Takeda
Phase 1 Completed
NCT02327169 2020-02-25
A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies
Takeda
Phase 1 Completed
NCT01899053 2019-10-30
A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies
Takeda
Phase 1 Completed
NCT01351350 2019-08-08
Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
Takeda
Phase 1 Completed